Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Gyre Therapeutics (GYRE) Long-Term Investments (2020 - 2025)

Gyre Therapeutics (GYRE) has disclosed Long-Term Investments for 8 consecutive years, with $49.7 million as the latest value for Q4 2023.

On a quarterly basis, Long-Term Investments changed N/A to $49.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was $49.7 million, a N/A change, with the full-year FY2023 number at $49.7 million, changed N/A from a year prior.
Long-Term Investments was $49.7 million for Q4 2023 at Gyre Therapeutics, up from $2.5 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $49.7 million in Q4 2023 to a low of $1.2 million in Q3 2020.